We have located links that may give you full text access.
Acute Effects of the Translocator Protein (TSPO) Drug Ligand FGIN-1-27 on Serum Testosterone and LH Levels in Male Sprague Dawley Rats.
Biology of Reproduction 2018 October 9
We reported that FGIN-1-27 (N, N-dihexyl-2-(4-fluorophenyl)indole-3-acetamide, FGIN), a synthetic ligand for translocator protein (TSPO, 18 kDa), increased serum testosterone levels in young and aged Brown Norway rats after its administration daily for 10 days. It is not known, however, how soon after treatment with FGIN serum testosterone rises, how long levels remain elevated after cessation of treatment, or whether the drug acts solely through TSPO. Adult Sprague Dawley male rats received a single ip dose of FGIN (1mg/kg BW). Serial blood samples were collected and serum testosterone and LH were assessed hourly throughout 24 hours. Testosterone concentration was maximal by 3 hours, remained significantly higher than the controls at 10 hours, and returned to the control level by 24 hours. Consistent with the in vivo study, culturing isolated Leydig cells with either FGIN (40μM) or LH (0.1ng/ml) resulted in significantly increased testosterone production by 30 mins, and the stimulatory effects persisted through 48 hours. At a very early (15 min) treatment time, however, FGIN significantly increased testosterone production but LH had not yet done so. Surprisingly, in vivo treatment with FGIN not only increased serum testosterone but also serum LH concentration, raising the possibility that FGIN may increase serum testosterone concentration by dual mechanisms.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app